Bruker Announces the New ultrafleXtreme MALDI-TOF/TOF Mass Spectrometer for Novel Applications Achievements Far Beyond Tradit...
May 21 2012 - 6:00AM
Business Wire
At ASMS 2012, Bruker announces the launch of the new
ultrafleXtreme™ MALDI TOF/TOF system. Bruker’s market
leading, top of the range product has been significantly enhanced
to offer both increased analytical power and entirely new
functionality, extending the applications envelope of MALDI TOF/TOF
far beyond the conventional concepts of what’s possible in
molecular histology, glycoprotein and biopharmaceuticals
analysis.
(Photo: Business Wire)
Already the acknowledged leader in Mass Spectrometry Imaging
(MSI), the next-generation ultrafleXtreme system
incorporates the Bruker patented smartbeam™ laser, now with
up to 2 kHz repetition rate with true-pixel image resolution at
20µm for proteins. This development marks a new milestone in the
pioneering smartbeam laser technology, designed and
manufactured exclusively by Bruker for unmatched performance in
MALDI mass spectrometry.
While biomarker discovery in large tissue-sample cohorts can now
be achieved at record high speed, Bruker has also significantly
extended the discovery potential of Molecular Histology with the
new ImageID™ workflow. The proprietary ImageID
workflow is a fully-integrated process to provide scientists with
integrated tissue maps for both protein distribution and
identification. More than 100 proteins are typically characterized
by the ImageID workflow, where consecutive histological
sections are processed in parallel to generate complementary
datasets in a single software environment for comprehensive
analysis. ImageID yields identifications of approximately
80% of all peptides observed in imaging measurements, also those
derived from high molecular weight proteins. For the first time,
the method can access fixed (FFPE) tissue, allowing molecular
histology to be applied to vast collections of archived clinical
samples to unlock a potential treasure chest of biomarker data in
cancer studies.
The ultrafleXtreme has also become the industry
trendsetter in tools for biopharmaceutical characterization with
patented Top-Down T3-Sequencing for revealing
terminal modifications, post-translational modifications (PTMs) and
sequence impurities. Bruker now presents its rapidly expanding
biologics customer base with high resolution intact biomolecule
analysis on the new ultrafleXtreme platform. The new
MALDI-TOF/TOF system leaps across the conventional boundary between
MALDI and electrospray ionization by generating multiply-charged
intact protein ions for measurements with mass resolution of
greater than 30,000, which can yield isotopic information for 30
kDa proteins, and larger protein molecular weight assignments with
better than 15 ppm mass accuracy. Achieved using the new
ultrafleXtreme FlashDetector™ and DHAP matrix innovations,
this intact protein bioanalytical ability represents a paradigm
change for biologics discovery, development and QC.
The ultrafleXtreme’s utility for the biopharmaceutical
industry and life-science research is further enhanced by Bruker’s
new GlycoQuest™ glycan search engine which retrieves glycan
structure candidates with unprecedented ease, enabling expert full
glycoprotein structure elucidation for every molecular
biologist.
“Precise intact biomolecule data at the speed and simplicity of
MALDI analysis with full glyco-structure reporting really completes
the picture for our biopharma customers,” commented Dr. Laura Main,
Bruker Daltonics’ Biopharmaceutical Market Manager.
About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of
high-performance scientific instruments and solutions for molecular
and materials research, as well as for industrial and applied
analysis. For more information, please visit www.bruker.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50283564&lang=en
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024